Loading
A phase 1/2 trial of Tislelizumab in hepatocellular carcinoma and colorectal cancer, run by Indaptus Therapeutics, Inc, active and no longer recruiting.
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05651022 by Indaptus Therapeutics, Inc, with 120 participants planned, started 2023-02-28 and due to reach its primary completion in 2027-06-30. Interventions recorded: Decoy20, Tislelizumab. Conditions listed: Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tislelizumab, Hepatocellular carcinoma, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tislelizumab, Immune checkpoint inhibitors.
Shares Tislelizumab, Immune checkpoint inhibitors.
Shares Tislelizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/